CD28 and acute myeloid leukemia: A second-generation CAR with a CD28 costimulatory domain demonstrated preclinical efficacy by targeting of the LeY antigen in mice bearing subcutaneous OVCAR3 ovarian cancer tumors [58] and a clinical trial was opened to determine the efficacy in patients with acute myeloid leukemia (AML).